These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11452683)

  • 1. Treatment of insomnia with zaleplon, a novel sleep medication.
    Doghramji PP
    Int J Clin Pract; 2001 Jun; 55(5):329-34. PubMed ID: 11452683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.
    Weitzel KW; Wickman JM; Augustin SG; Strom JG
    Clin Ther; 2000 Nov; 22(11):1254-67. PubMed ID: 11117652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of zaleplon in the treatment of insomnia.
    Israel AG; Kramer JA
    Ann Pharmacother; 2002 May; 36(5):852-9. PubMed ID: 11978165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of zaleplon at peak plasma levels.
    Mangano RM
    Int J Clin Pract Suppl; 2001 Jan; (116):9-13. PubMed ID: 11219331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M; Plosker GL
    Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualizing therapy for early, middle-of-the-night and late-night insomnia.
    Scharf MB
    Int J Clin Pract Suppl; 2001 Jan; (116):20-4. PubMed ID: 11219329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group.
    Hedner J; Yaeche R; Emilien G; Farr I; Salinas E
    Int J Geriatr Psychiatry; 2000 Aug; 15(8):704-12. PubMed ID: 10960882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
    Elie R; Rüther E; Farr I; Emilien G; Salinas E
    J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of hypnotic flexibility on patterns of clinical use.
    Lader MH
    Int J Clin Pract Suppl; 2001 Jan; (116):14-9. PubMed ID: 11219327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.
    Fry J; Scharf M; Mangano R; Fujimori M
    Int Clin Psychopharmacol; 2000 May; 15(3):141-52. PubMed ID: 10870872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-risk assessment of zaleplon in the treatment of insomnia.
    Barbera J; Shapiro C
    Drug Saf; 2005; 28(4):301-18. PubMed ID: 15783240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.
    Stone BM; Turner C; Mills SL; Paty I; Patat A; Darwish M; Danjou P
    Br J Clin Pharmacol; 2002 Feb; 53(2):196-202. PubMed ID: 11851645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance.
    Paul MA; Gray G; Kenny G; Pigeau RA
    Aviat Space Environ Med; 2003 Dec; 74(12):1263-70. PubMed ID: 14692469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of insomnia--the role of zaleplon.
    Richardson GS; Roth T; Kramer JA
    MedGenMed; 2002 Mar; 4(1):9. PubMed ID: 11965211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies.
    Rosenberg RP
    Ann Clin Psychiatry; 2006; 18(1):49-56. PubMed ID: 16517453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia.
    Heydorn WE
    Expert Opin Investig Drugs; 2000 Apr; 9(4):841-58. PubMed ID: 11060714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
    Belleville G; Morin CM
    Health Psychol; 2008 Mar; 27(2):239-48. PubMed ID: 18377143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of sedative hypnotics in older patients with insomnia.
    Ancoli-Israel S; Richardson GS; Mangano RM; Jenkins L; Hall P; Jones WS
    Sleep Med; 2005 Mar; 6(2):107-13. PubMed ID: 15716214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats.
    Noguchi H; Kitazumi K; Mori M; Shiba T
    J Pharmacol Sci; 2004 Mar; 94(3):246-51. PubMed ID: 15037809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for flexibility in dosing of hypnotic agents.
    Doghramji K
    Sleep; 2000 Feb; 23 Suppl 1():S16-20; discussion S21-2. PubMed ID: 10755804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.